Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSAKiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing therapies for immune-mediated and inflammatory diseases. Founded in 2015 and headquartered in Bermuda, the company leverages its platform to create innovative treatments aimed at addressing unmet medical needs, particularly in the fields of dermatology, rheumatology, and other immunology-related conditions.
Company News
Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.
Kiniksa Pharmaceuticals announces plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, with the trial expected to initiate in mid-2025 and Phase 2 data expected in the second half of 2026.
Kiniksa Pharmaceuticals announced that country star Carly Pearce has joined their Life DisRPted campaign to raise awareness for recurrent pericarditis. The company also reported strong Q1 2025 financial results for their ARCALYST product, with net product revenue of $137.8 million and increased 2025 revenue guidance.
The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.
Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
